Melanocyte Stimulating Hormone Receptor – Drugs In Development, 2021

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 11 molecules.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 1 and 5 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Central Nervous System, Genetic Disorders, Infectious Disease, Ophthalmology, Cardiovascular, Musculoskeletal Disorders, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Porphyria (Erythropoietic Protoporphyri), Rheumatoid Arthritis, Uveitis, Vitiligo, Acne Vulgaris, Acute Ischemic Stroke, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Pulmonary Fibrosis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Ulcerative Colitis.

The latest report Melanocyte Stimulating Hormone Receptor – Drugs In Development, 2021, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

– The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Clinuvel Pharmaceuticals Ltd

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Mitsubishi Tanabe Pharma Corp

Palatin Technologies Inc

SynAct Pharma AB

Viewpoint Molecular Targeting LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Ltd

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Mitsubishi Tanabe Pharma Corp

Palatin Technologies Inc

SynAct Pharma AB

Viewpoint Molecular Targeting LLC

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles

afamelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dersimelagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Parvysmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-9643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones

Featured News & Press Releases

Jul 07, 2021: SynAct Pharma announces additional data from the phase 2a trial of AP1189 in covid-19 infected patients and reminds of management call to discuss results

Jul 02, 2021: SynAct Pharma hosts conference call on positive data from a phase 2a trial of AP1189 in Covid-19 infected patients

Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis

Jun 30, 2021: SynAct Pharma announces positive data from a phase 2a trial of AP1189 in covid-19 infected patients

Jun 29, 2021: Palatin announces positive end-of-phase 2 meeting with FDA on PL9643 for the treatment of dry eye disease

Jun 23, 2021: SynAct Pharma files patent applications related to AP1189 derived APIs and oral formulations

Jun 07, 2021: First stroke patient treated with afamelanotide

Jun 01, 2021: SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

May 14, 2021: Palatin hosting key opinion leader webinar in role of melanocortin agonists in inflammation and the treatment of ocular indications

May 14, 2021: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.

May 04, 2021: SynAct Pharma expands AP1189 BEGIN study in rheumatoid arthritis UK version

May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting

Apr 20, 2021: Palatin announces two presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Apr 13, 2021: SynAct strengthens IP portfolio - Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version

Mar 31, 2021: Phase-2 clinical trial of MT-7117 initiated in the U.S., Canada, and Europe for the rare disease, diffuse cutaneous systemic sclerosis (dcSSc)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Clinuvel Pharmaceuticals Ltd, 2021

Pipeline by Eton Pharmaceuticals Inc, 2021

Pipeline by Mallinckrodt Plc, 2021

Pipeline by Mitsubishi Tanabe Pharma Corp, 2021

Pipeline by Palatin Technologies Inc, 2021

Pipeline by SynAct Pharma AB, 2021

Pipeline by Viewpoint Molecular Targeting LLC, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports